No Data
No Data
Earnings Preview: SAGE to Report Financial Results Post-market on April 29
Morgan Stanley Maintains Sage Therapeutics(SAGE.US) With Hold Rating, Maintains Target Price $9
Cautious Outlook for SAGE Therapeutics Amid Strategic Uncertainty and Financial Challenges
Press Release: Sage Therapeutics to Report First Quarter 2025 Financial Results on Tuesday, April 29, 2025
Sage Alliance Schools Expands Therapeutic School to New York City Opening September 2025
RBC Raises Price Target on SAGE Therapeutics to $7 From $6, Keeps Sector Perform, Speculative Risk
Newbee4 : $Bridger Aerospace (BAER.US)$